Literature DB >> 25361780

DRESS associated with perampanel administration in a child with drug-resistant epilepsy.

Kozue Shimabukuro1, Frances Gibbon2, Justin Kerstetter2, Cynthia Tinsley2, Stephen Ashwal2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25361780      PMCID： PMC4276402          DOI： 10.1212/WNL.0000000000001052

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  7 in total

Review 1.  Adverse effects and safety profile of perampanel: a review of pooled data.

Authors:  Fergus Rugg-Gunn
Journal:  Epilepsia       Date:  2014-01       Impact factor: 5.864

Review 2.  Severe adverse cutaneous reactions to drugs.

Authors:  J C Roujeau; R S Stern
Journal:  N Engl J Med       Date:  1994-11-10       Impact factor: 91.245

Review 3.  Drug reaction with Eosinophilia and Systemic Symptoms (DRESS) / Drug-induced Hypersensitivity Syndrome (DIHS): a review of current concepts.

Authors:  Paulo Ricardo Criado; Roberta Fachini Jardim Criado; João de Magalhães Avancini; Claudia Giuli Santi
Journal:  An Bras Dermatol       Date:  2012 May-Jun       Impact factor: 1.896

4.  Perampanel: a selective AMPA antagonist for treating seizures.

Authors:  Gregory L Krauss
Journal:  Epilepsy Curr       Date:  2013-11       Impact factor: 7.500

5.  Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies.

Authors:  Bernhard J Steinhoff; Elinor Ben-Menachem; Philippe Ryvlin; Simon Shorvon; Lynn Kramer; Andrew Satlin; David Squillacote; Haichen Yang; Jin Zhu; Antonio Laurenza
Journal:  Epilepsia       Date:  2013-05-10       Impact factor: 5.864

6.  Discovery of 2-(2-oxo-1-phenyl-5-pyridin-2-yl-1,2-dihydropyridin-3-yl)benzonitrile (perampanel): a novel, noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropanoic acid (AMPA) receptor antagonist.

Authors:  Shigeki Hibi; Koshi Ueno; Satoshi Nagato; Koki Kawano; Koichi Ito; Yoshihiko Norimine; Osamu Takenaka; Takahisa Hanada; Masahiro Yonaga
Journal:  J Med Chem       Date:  2012-12-04       Impact factor: 7.446

7.  New drug classes for the treatment of partial onset epilepsy: focus on perampanel.

Authors:  Jerry J Shih; William O Tatum; Leslie A Rudzinski
Journal:  Ther Clin Risk Manag       Date:  2013-07-08       Impact factor: 2.423
  7 in total
  5 in total

Review 1.  The Pharmacology and Toxicology of Third-Generation Anticonvulsant Drugs.

Authors:  Paul LaPenna; Laura M Tormoehlen
Journal:  J Med Toxicol       Date:  2017-08-16

Review 2.  Cutaneous Adverse Effects of Neurologic Medications.

Authors:  Eman Bahrani; Chloe E Nunneley; Sylvia Hsu; Joseph S Kass
Journal:  CNS Drugs       Date:  2016-03       Impact factor: 6.497

Review 3.  Perampanel in the management of partial-onset seizures: a review of safety, efficacy, and patient acceptability.

Authors:  Andreas Schulze-Bonhage; Mandy Hintz
Journal:  Patient Prefer Adherence       Date:  2015-08-11       Impact factor: 2.711

4.  Drug reaction with eosinophilia and systemic symptoms (DRESS) in children.

Authors:  Francesca Mori; Carlo Caffarelli; Silvia Caimmi; Paolo Bottau; Lucia Liotti; Fabrizio Franceschini; Fabio Cardinale; Roberto Bernardini; Giuseppe Crisafulli; Francesca Saretta; Elio Novembre
Journal:  Acta Biomed       Date:  2019-01-29

5.  Exploring the Evidence for Broad-Spectrum Effectiveness of Perampanel: A Systematic Review of Clinical Data in Generalised Seizures.

Authors:  Eugen Trinka; Simona Lattanzi; Kate Carpenter; Tommaso Corradetti; Bruna Nucera; Fabrizio Rinaldi; Rohit Shankar; Francesco Brigo
Journal:  CNS Drugs       Date:  2021-07-07       Impact factor: 5.749
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.